LPCAT3 is essential for leukemia progression and represents a therapeutic vulnerability in AML Authors: Mutian Cao, Lizhen Cong, Yifei He, Mingyue Hao, Yuanyi Ling, Wanting Li, Mingyue Zhang, Weiping Yuan, Yajing Chu Published: 2026 ABSTRACT Acute myeloid leukemia (AML) is a group of genetically and clinically heterogeneous malignancies characterized by clonal expansion of immature myeloid progenitors and profound disruption of normal hematopoiesis. Emerging evidence suggests that alterations in cellular homeostasis shape cancer progression. However, the mechanisms underlying AML progression remain largely unclear. Here, we identify lysophosphatidylcholine acyltransferase 3 (LPCAT3), a key enzyme of the Lands’ cycle, as a critical regulator of AML progression. Analysis of public transcriptomic datasets and patient-derived CD34+ cells revealed robust LPCAT3 overexpression in AML and an association between high LPCAT3 levels and inferior overall AML patient survival. Suppression of LPCAT3 by shRNA or CRISPR–Cas9 in MOLM-13 and THP-1 cells markedly impaired proliferation, induced apoptosis, and caused G0/G1 cell-cycle arrest. Conversely, enforced overexpression promoted cell survival. In xenograft murine models, LPCAT3 depletion reduced leukemic burden. RNA-seq following LPCAT3 loss showed that genes differentially expressed were significantly enriched in granulocyte chemotaxis–related pathways, suggesting a role of LPCAT3 in modulation of leukemic differentiation programs and microenvironmental interactions. Collectively, these data established that LPCAT3 as a previously unrecognized mediator of AML cell fitness and as a potential therapeutic target. 1. INTRODUCTION Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy with a poor prognosis despite current therapeutic strategies.1,2 Beyond genetic alterations, metabolic and membrane remodeling processes have emerged as critical regulators of leukemic progression.3,4 Lysophosphatidylcholine acyltransferases (LPCATs) constitute an enzyme family responsible for catalyzing the reacylation of lysophosphatidylcholine, thereby generating phosphatidylcholine,5 and controlling the composition of cellular membranes.6 By regulating phospholipid saturation and membrane fluidity, LPCATs influence receptor distribution,7 intracellular signaling,8 and the generation of bioactive lipid mediators.5,9 Among them, LPCAT3 is distinguished by its preference for polyunsaturated fatty acids (PUFAs) such as arachidonic acid,10 linking it to inflammation,11,12 oxidative stress,13,14 and ferroptosis.15–17 LPCAT3 catalyzes the incorporation of PUFAs into the sn-2 position of phospholipids, thereby contributing to phospholipid remodeling and overall lipid homeostasis.18 LPCAT3 is regulated by nuclear receptors such as liver X receptor (LXR) and peroxisome proliferator-activated receptors (PPARs) and is critically involved in the regulation of membrane composition, lipoprotein secretion, and intestinal lipid absorption, illustrating its canonical role in lipid metabolism and systemic lipid regulation.18,19 Beyond its enzymatic activity, recent studies have also implicated LPCAT3 in modulating membrane biophysical properties that influence receptor clustering and downstream signaling pathways, including those involved in inflammation and cell stress responses.20,21 Recent studies have implicated the role of LPCAT3 in various solid tumors.15 For instance, LPCAT3 regulates the proliferation and metastasis of serous ovarian cancer by modulating arachidonic acid metabolism10,22; It is also involved in modulating immune cell infiltration and influences the clinical prognosis of patients with clear cell renal cell carcinoma (ccRCC) by mediating ferroptosis and endoplasmic reticulum stress23; moreover, ferroptosis-related gene signatures involving LPCAT3 have been used to stratify triple-negative breast cancer and guide treatment prioritization.24,25 Public transcriptomic analyses and pan-cancer studies have shown that LPCAT3 is broadly expressed in hematopoietic tissues and is upregulated in AML, where its expression correlates with poor prognosis.22,26 This suggests that LPCAT3 may serve as a metabolic regulator of hematopoietic differentiation and stress adaptation.27 Among diverse genetic subtypes of AML, MLL-AF9-rearranged AML represents one of the most aggressive forms, frequently associated with aberrant activation of stem cell–like transcriptional programs, high relapse rates, and poor clinical outcomes.28 Despite intensive chemotherapy and emerging targeted therapies, patients with MLL-AF9 AML often show limited therapeutic responses, and long-term survival remains unsatisfactory, highlighting a critical unmet clinical need for the identification of novel molecular vulnerabilities in this subtype.29 In this context, the specific role of LPCAT3 in AML, particularly in MLL-AF9–driven leukemia, and the underlying molecular mechanisms remain largely unexplored. Here, we investigated the role of LPCAT3 in AML using functional assays and transcriptomic profiling. We identified that LPCAT3 depletion delays cell proliferation, induces apoptosis, and alters cell-cycle progression in AML cells. We further demonstrated that LPCAT3 regulates the transcriptional programs associated with granulocyte chemotaxis pathways and immune signaling. 2. MATERIALS AND METHODS 2.1. Data source and processing Gene expression data for AML were obtained from publicly available databases, including The Cancer Genome Atlas (TCGA) acute myeloid leukemia (LAML) cohort (n = 173), the Oregon Health & Science University (OHSU) dataset (n = 672), and Genotype-Tissue Expression (GTEx; normal controls, n = 70). Expression levels were retrieved from the GEPIA2 online platform and reported as transcripts per million (TPM) values, which were log2-transformed for downstream analysis. For our own RNA sequencing (RNA-seq) experiments, raw sequencing reads were first subjected to quality control and filtering. High-quality reads were aligned to the human reference genome using HISAT2. Differentially expressed genes were identified using the DESeq2 R package. RNA-seq data reported in this research were deposited in the Genome Sequence Archive (GSA, National Genomics Data Center, China National Center for Bioinformation) under accession number HRA013416. 2.2. Cell culture Human AML cell lines, including MOLM-13 and THP-1, were obtained from the State Key Laboratory of Experimental Hematology (Tianjin, China). MOLM-13 and THP-1 cells were cultured at a density of 1 to 2 × 106 cells/mL in RPMI-1640 medium (Gibco, Grand Island, New York; Cat#C11875500BT) supplemented with 10% fetal bovine serum (FBS; Gibco; Cat#A5256701) and 1% penicillin–streptomycin (Gibco; Cat#15140122). All cells were maintained at 37°C in a humidified incubator (Thermo Fisher Scientific, Waltham, Massachusetts) with 5% CO2. 2.3. Genetic manipulation of LPCAT3 The short hairpin RNA (shRNA: gatcgCATCTTCAAACGACTCAAGTTCTCGAGAACTTGAGTCGTTTGAAGATGTTTTTT) constructs targeting LPCAT3 were designed and synthesized by Tsingke Biotechnology (Beijing, China) and cloned into the pLVX-shRNA-Puro-EF1a vector. The single guide RNA (sgRNA) sequences targeting LPCAT3 were synthesized using the Golden Gate assembly method (NEB, Ipswich, Massachusetts). The sgRNA sequences were as follows: sgRNA-1, 5′-GCTGTTGACTACTTTGACGG-3′; sgRNA-2, 5′-GCACAATACACAGCAGGGAG-3′; sgRNA-3, 5′-TAAGATGGCGTCCTCAGCGG-3′. These sgRNAs were cloned into the LentiCRISPR-v2 vector. The LPCAT3 overexpression plasmid was generated by YouBio (Changsha, Hunan, China) using pCDH-MSCV-EF1-mCherry vector. All vectors were packaged into lentiviruses together with psPAX2 and MD2.G plasmids in HEK293T cells. For shRNA- and overexpression-based systems, a plasmid ratio of 7:5:3 (target plasmid:psPAX2:MD2.G) was used, while for sgRNA-mediated knockout, a ratio of 4:3:2 was applied. For infection, cells were seeded at a density of 1 × 105 cells per well in 24-well plates. A total of 100 μL of 1:10 concentrated lentivirus was added to each well, and the culture volume was adjusted to 1 mL with complete medium containing 6 μg/mL polybrene (Sigma-Aldrich, St. Louis, Missouri). Plates were centrifuged at 1800 rpm at 33°C for 90 minutes. After infection, mCherry-positive cells were sorted using a BD FACSAria III cell sorter (BD, San Jose, California) and subsequently maintained in RPMI-1640 medium supplemented with 10% FBS. 2.4. Quantitative real-time polymerase chain reaction Total RNA was extracted using an RNA extraction kit (Tsingke Biotechnology) according to the manufacturer’s instructions. cDNA was synthesized from 1 μg of total RNA using a reverse transcription kit (GenScript, Nanjing, Jiangsu, China). Quantitative polymerase chain reaction (qPCR) was performed with SYBR Green Master Mix (Abclonal, Wuhan, Hubei, China) on a QuantStudio 5 Real-Time PCR System (Thermo Fisher Scientific). Relative gene expression levels were calculated using the ΔCt method with 18S as the internal control. The primer sequences of LPCAT3 (5′→3′) were as follows, with additional primer sequences provided in Table S4, https://links.lww.com/BS/A168: h-LPCAT3-forward: GGAGCTGAGCCTTAACAAGTT h-LPCAT3-reverse: CAAAGCAAAGGGGTAACCCAG 2.5. Western blotting analysis Western blotting was performed as previously described.30 The following primary antibodies were used: anti-LPCAT3 (1:1000; Abclonal), anti-GAPDH (1:5000; Abclonal), β-actin (1:5000; Abclonal). Secondary antibodies (anti-mouse or anti-rabbit, depending on host species) were used at a dilution of 1:10,000. 2.6. Cell proliferation assay Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8) assay (Yeasen, Shanghai, China; Cat#40203ES80). Briefly, cells were seeded into 96-well plates at a density of 2000 cells per well in 100 μL of complete medium. From day 0 to day 5, 10 μL of CCK-8 reagent was added to each well daily, followed by incubation at 37°C in a humidified incubator with 5% CO2 for 4 hours. Absorbance at 450 nm was measured using a microplate reader (BioTek, Winooski, Vermont). Data were analyzed and visualized using GraphPad Prism 10 (GraphPad Software, San Diego, California). 2.7. Cell-cycle analysis Cell-cycle distribution was analyzed using allophycocyanin (APC)- or fluorescein isothiocyanate (FITC)-conjugated Ki-67 antibodies in combination with Hoechst 33342 staining. Cells were fixed and permeabilized with the BD IntraSure™ kit (BD Biosciences, San Jose, California; Cat#641776) according to the manufacturer’s instructions. Briefly, 1 × 106 cells were washed with PBS and resuspended in 100 μL Reagent A, followed by incubation at room temperature for 5 minutes. Subsequently, 1 mL of 1× BD FACS lysing solution was added, vortexed, and incubated for 10 minutes at room temperature. Cells were then pelleted by centrifugation at 2000 rpm for 5 minutes, resuspended in 50 μL Reagent B, and stained with 3 μL APC- or FITC-conjugated Ki-67 antibody for 30 minutes at room temperature in the dark. After washing with PBS, cells were resuspended and incubated with Hoechst 33342 (20 ng/μL, added 2 minutes before acquisition). Samples were analyzed on a flow cytometer (BD Biosciences). 2.8. Cell apoptosis analysis Apoptosis was assessed using the APC-Annexin V/7-AAD Apoptosis Detection Kit (BD Biosciences) according to the manufacturer’s protocol. Briefly, 1 × 106 cells were harvested, washed once with 1 mL binding buffer, and pelleted by centrifugation at 1500 rpm for 5 minutes. Cells were resuspended in 100 μL binding buffer and incubated with 5 μL APC-Annexin V antibody and 5 μL 7-AAD for 15 minutes at room temperature in the dark. After incubation, 300 μL binding buffer was added to each sample, and apoptosis was analyzed within 1 hour using a flow cytometer (BD Biosciences). 2.9. Animal experiments NOD-Prkdcem26Cd52Il2rgem26Cd22/Nju (NCG) mice (6–8 weeks old, female, purchased from GemPharmatech, Nanjing, Jiangsu, China) were used for xenotransplantation studies. Mice were irradiated with a single dose of 1.2 Gy and, 6 hours later, transplanted via tail vein injection with 1 × 106 cells suspended in 200 μL PBS. At 21 days post-transplantation, mice were sacrificed, and spleen and bone marrow were harvested for flow cytometric analysis. All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the State Key Laboratory of Experimental Hematology (Tianjin, China) and conducted in accordance with institutional guidelines for the care and use of laboratory animals. 2.10. Small-interfering RNAs transfection Small-interfering RNA (siRNA) oligonucleotides targeting CCL24 (siCCL24) and a negative control siRNA (NC-siRNA) were synthesized by Suzhou GenePharma Co., Ltd. (Suzhou, Jiangsu, China). siRNA transfection was performed in AML cell lines using Lipofectamine™ 3000 (Invitrogen, Carlsbad, CA, USA; Cat#L3000015) according to the manufacturer’s instructions. Briefly, 1 × 106 cells were seeded per well in 6-well plates and transfected with 5 μL of 20 μM siRNA and 5 μL Lipofectamine 3000 diluted in 500 μL Opti-MEM (Invitrogen; Cat#31985070) and 500 μL complete culture medium. Cells were harvested 24 hours after transfection for subsequent analyses. Knockdown efficiency was evaluated by measuring CCL24 protein levels using a Human CCL24 ELISA Kit (Solarbio, Beijing, China; Cat#SEKH-0063) according to the manufacturer’s instructions, and apoptosis and cell-cycle distribution were analyzed by flow cytometry. The siRNA sequences (5′–3′) were as follows: CCL24-siRNA-1, forward GGCCUGAUGACCAUAGUAATT and reverse UUACUAUGGUCAUCAGGCCTT; CCL24-siRNA-2, forward CCUGCUGCAUGUUCUUUGUTT and reverse ACAAAGAACAUGCAGCAGGTT; CCL24-siRNA-3, forward GUCCAGAGGUACAUGAAGATT and reverse UCUUCAUGUACCUCUGGACTT; and NC-siRNA, forward UUCUCCGAACGUGUCACGUTT and reverse ACGUGACACGUUCGGAGAATT. 2.11. RNA sequencing RNA-seq was performed using in vitro–cultured MOLM-13 cells transduced with non-targeting control sgRNA (sgNT) or sgRNA targeting LPCAT3 (sgLPCAT3-3). Cells were maintained under standard culture conditions and harvested at comparable confluency. Total RNA was extracted using an RNA extraction kit (Tsingke Biotechnology) according to the manufacturer’s instructions. RNA quality and integrity were assessed prior to library preparation. Samples meeting quality control criteria were subsequently subjected to RNA-seq. 2.12. Statistical analysis All statistical analyses were performed using GraphPad Prism 10. Data are presented as the mean ± standard deviation (SD). The number of biological and/or technical replicates for each experiment is specified in the corresponding figure legends. For comparisons between 2 groups, the unpaired Student’s t test was used. For experiments involving multiple groups and/or time-course measurements, 2-way analysis of variance (ANOVA) was applied, followed by appropriate post hoc comparisons as indicated in the figure legends. A p value <0.050 was considered statistically significant. Statistical significance is denoted as follows: ns, p > 0.050; *p < 0.050; **p < 0.010; ***p < .001. 3. RESULTS 3.1. Elevated LPCAT3 expression in AML patients correlates with adverse AML clinical features To explore which LPCAT family member might be functionally relevant in AML, we first assessed their expression profiles by analyzing transcript levels in bone marrow samples from AML patients and healthy controls obtained from the TCGA-LAML and GTEx datasets.31 Within the LPCAT family, only LPCAT2 and LPCAT3 displayed elevated expression in AML relative to normal samples, and LPCAT3 exhibited the strongest upregulation (Fig. 1A). To further evaluate their clinical significance, we performed survival analyses using the TCGA cohort. Notably, high LPCAT3 expression, but not LPCAT2, was significantly associated with shorter overall survival in AML patients, as demonstrated by Kaplan–Meier survival curves and log-rank tests (Fig. 1B). These findings suggest that LPCAT3, compared with other LPCAT family members, is the most functionally relevant gene associated with AML progression and prognosis. LPCAT3 is upregulated in AML and correlates with patient survival. (A) Transcriptional levels of LPCAT1, LPCAT2, LPCAT3, LPCAT4 in AML patients vs normal controls. Data were obtained from the TCGA-LAML cohort using GEPIA2, presented as −log2(TPM + 1). Expression levels were compared between 70 normal samples and 173 AML samples. (B) Kaplan–Meier survival analysis of TCGA-LAML patients stratified into high and low LPCAT1, LPCAT2, LPCAT3, LPCAT4 expression groups. (C) Transcriptional levels of LPCAT3 in 31 different cancers. Data were obtained from TCGA using GEPIA2. (D) RT-qPCR analysis for transcriptional levels of LPCAT3 in BMMNC from AML patients (n = 9) relative to healthy donors (n = 7). Data are presented as mean ± SD. Statistical significance was determined using an unpaired Student t test. (E) Transcriptional levels of LPCAT3 in AML stratified by common genetic alterations. (F) Transcriptional levels of LPCAT3 across hematopoietic lineages from Bloodspot. *p < 0.050, ***p < .001. AML = acute myeloid leukemia, BMMNC = bone marrow mononuclear cells, LAML = acute myeloid leukemia, LPCAT3 = lysophosphatidylcholine acyltransferase 3, RT-qPCR = quantitative real-time polymerase chain reaction, SD = standard deviation, TCGA = The Cancer Genome Atlas. Pan-cancer analysis31 revealed that LPCAT3 expression was elevated in several malignancies, including glioblastoma multiforme (GBM), kidney chromophobe (KICH), lower-grade glioma (LGG), and testicular germ cell tumors (TGCT), whereas it was downregulated in adrenocortical carcinoma (ACC) (Fig. 1C). These results suggest that LPCAT3 may play distinct and context-dependent roles across different tumor types. To validate these findings in primary clinical specimens, we measured LPCAT3 expression in BMMNC isolated from 3 newly diagnosed AML patients and healthy donors (Table S1, https://links.lww.com/BS/A168). Consistent with transcriptomic database analyses, LPCAT3 levels were higher in the AML-derived BMMNC compared with normal counterparts (Fig. 1D). We further examined LPCAT3 expression across AML patients stratified by 13 common genetic mutations.32 However, LPCAT3 expression did not show a strong enrichment in any particular mutation-defined subgroup, suggesting that its upregulation in AML may occur independently of specific genetic alterations (Fig. 1E). Further analysis of LPCAT3 mRNA expression using the human leukemia database Bloodspot33 revealed that its expression is the lowest in polymorphonuclear cells (neutrophils) and monocytes, but elevated across various AML subtypes (Fig. 1F). 3.2. Genetic suppression of LPCAT3 delayed proliferation and induced apoptosis To investigate the functional role of LPCAT3 in AML cell proliferation and survival, we established a shRNA-mediated LPCAT3 stable knockdown cell line with MOLM-13 cells. Efficient knockdown was validated at both the protein level and mRNA level (Fig. 2A, B). Functional assays were subsequently performed to assess the impact of LPCAT3 depletion on cell-cycle dynamics. Staining with Ki-67 and Hoechst 33342 demonstrated a pronounced reduction in the percentage of cells advancing into the S/G2/M phases, along with an increased accumulation at the G0/G1 phase (Fig. 2C, D), indicating that loss of LPCAT3 impairs cell-cycle progression. To evaluate whether this disruption also affects cell survival, we performed flow cytometry using Annexin V staining, which demonstrated a significant increase in apoptotic cell populations following LPCAT3 knockdown (Fig. 2E, F). CCK-8 proliferation assays further demonstrated that LPCAT3-depleted cells exhibited markedly reduced growth over a 5-day period (Fig. 2G), supporting the requirement of LPCAT3 for maintaining proliferative capacity in MOLM-13 cells. shRNA-mediated suppression of LPCAT3 impairs proliferation, induces apoptosis, and enforces cell-cycle arrest in AML cells. (A) Western blotting for LPCAT3 expression in MOLM-13 cell line transduced with scramble or shLPCAT3. (B) RT-qPCR analysis for transcriptional levels of LPCAT3 in MOLM-13 cell line transduced with scramble or shLPCAT3. Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (C–D) The cell-cycle analysis of MOLM-13 cell line transduced with scramble or shLPCAT3. Flow cytometric analysis of cell cycle in MOLM-13 cell line (C). Quantification of G0, G1, S/G2/M phases in MOLM-13 cell line (D). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (E–F) The apoptosis analysis of MOLM-13 cell line transduced with scramble or shLPCAT3. Flow cytometry plots of apoptotic ratio in MOLM-13 cell line (E). Statistical analysis of apoptotic ratio in MOLM-13 cell line (F). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (G) Proliferation curves of scramble or shLPCAT3 groups in MOLM-13 cell line were measured by CCK-8. Data are presented as mean ± SD (n = 3). Statistical significance was determined using 2-way ANOVA. (H) Western blotting for LPCAT3 expression in THP-1 cell line transduced with scramble or shLPCAT3. (I) RT-qPCR analysis for transcriptional levels of LPCAT3 in THP-1 cell line transduced with scramble or shLPCAT3. Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (J–K) The cell-cycle analysis of THP-1 cell line transduced with scramble or shLPCAT3. Flow cytometric analysis of cell cycle in THP-1 cell line (J). Quantification of G0, G1, S/G2/M phases in THP-1 cell line (K). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (L–M) The apoptosis analysis of THP-1 cell line transduced with scramble or shLPCAT3. Flow cytometry plots of apoptotic ratio in THP-1 cell line (L). Statistical analysis of apoptotic ratio in THP-1 cell line (M). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (N) Proliferation curves of scramble or shLPCAT3 groups in THP-1 cell line were measured by CCK-8. Data are presented as mean ± SD (n = 3). Statistical significance was determined using two-way ANOVA. *p < 0.050, **p < 0.010, ***p < .001. AML = acute myeloid leukemia, ANOVA = analysis of variance, LPCAT3 = lysophosphatidylcholine acyltransferase 3, RT-qPCR = quantitative real-time polymerase chain reaction, SD = standard deviation. We further confirmed these findings in another AML cell line, THP-1. Stable knockdown of LPCAT3 was validated at both protein and transcript levels (Fig. 2H, I). Consistently, Ki-67/Hoechst 33342 staining indicated a pronounced decrease in cell-cycle entry, with more cells arrested in G0/G1 phase (Fig. 2J, K). Annexin V–based apoptosis assays demonstrated a substantial elevation of apoptotic cells in the LPCAT3-deficient THP-1 population (Fig. 2L, M), and proliferation assays over 5 days confirmed reduced growth rates compared with control cells (Fig. 2N). Taken together, these results demonstrate that shRNA-mediated LPCAT3 depletion consistently disrupts cell-cycle progression, enhances apoptosis, and suppresses proliferation in AML cells. The findings indicate that LPCAT3 plays a critical role in supporting AML cell growth and survival. 3.3. CRISPR–Cas9–mediated LPCAT3 targeted knockout suppressed AML cell growth To further investigate the functional role of LPCAT3 in AML cell growth and survival, we performed genetic ablation of LPCAT3 in MOLM-13 cells using CRISPR–Cas9 technology. Effective LPCAT3 ablation was confirmed at the protein level by immunoblotting (Fig. 3A), and further confirmed by qPCR in all three CRISPR-edited MOLM-13 lines (Fig. 3B). CRISPR–Cas9 LPCAT3 knockout phenocopies shRNA-mediated depletion in AML cells. (A) Western blotting for LPCAT3 expression in MOLM-13 cell line transduced with sg-control and 3 independent sgRNAs. (B) RT-qPCR analysis for transcriptional levels of LPCAT3 in MOLM-13 cell line transduced with sg-control and three independent sgRNAs. Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (C–D) The cell-cycle analysis of MOLM-13 cell line with sg-control and three independent sgRNAs. Flow cytometric analysis of cell cycle in MOLM-13 cell line (C). Quantification of G0, G1, S/G2/M phases in MOLM-13 cell line (D). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (E–F) The apoptosis analysis of MOLM-13 cell line with sg-control and 3 independent sgRNAs. Flow cytometry plots of apoptotic ratio in MOLM-13 cell line (E). Statistical analysis of apoptotic ratio in MOLM-13 cell line (F). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (G) Proliferation curves of sg-control or 3 sgLPCAT3 groups in MOLM-13 cell line were measured by CCK-8. Data are presented as mean ± SD (n = 3). Statistical significance was determined using 2-way ANOVA. *p < 0.050, **p < 0.010, ***p < .001. AML = acute myeloid leukemia, ANOVA = analysis of variance, LPCAT3 = lysophosphatidylcholine acyltransferase 3, RT-qPCR = quantitative real-time polymerase chain reaction, SD = standard deviation, sgRNA = single guide RNA, shRNA = short hairpin RNA. Functional characterization of LPCAT3-knockout cells revealed a marked impairment in cell-cycle progression. Ki-67-based flow cytometry demonstrated a substantial reduction in the fraction of cells entering S and G2/M phases, with a concomitant accumulation in G1 phase (Fig. 3C, D). To assess the impact of LPCAT3 loss on cell survival, apoptosis was measured using Annexin V staining, which revealed an increase in apoptotic cell populations in the knockout lines compared with controls (Fig. 3E, F). Consistent with the LPCAT3-shRNA results, CCK-8 assays showed that all three LPCAT3-knockout cell lines proliferated markedly slower than controls over 5 days (Fig. 3G). Collectively, this evidence supports the conclusion that LPCAT3 is a critical regulator of AML cell survival and proliferation, and highlights its potential as a therapeutic target for interventions aimed at impairing AML growth. 3.4. LPCAT3 overexpression accelerates AML cell proliferation To better elucidate the role of LPCAT3 in AML cell biology, we investigate the consequences of LPCAT3 overexpression in MOLM-13 cells. MOLM-13 cells were engineered to stably express exogenous LPCAT3 and overexpression was confirmed at both the transcript and protein levels (Fig. 4A, B). Flow cytometry analysis using Annexin V staining revealed that enforced LPCAT3 expression resulted in a decrease in apoptotic cells compared with empty vector control cells (Fig. 4C, D). In parallel, cell-cycle analysis using Ki-67 staining demonstrated accelerated cell-cycle progression in LPCAT3-overexpressing cells, with more cells entering S/G2/M phases compared with controls (Fig. 4E, F). Consistently, CCK-8 assays showed that LPCAT3-overexpressing cells proliferated faster than controls (Fig. 4G). These observations indicate that elevated LPCAT3 levels accelerate cell-cycle progression, thereby contributing to the enhanced proliferation observed. Enforced expression of LPCAT3 promotes proliferation, suppresses apoptosis, and accelerates cell-cycle progression in AML cells. (A) RT-qPCR analysis for transcriptional levels of LPCAT3 in MOLM-13 cell line transduced with empty vector and a LPCAT3-overexpressing plasmid (LPCAT3-OE). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (B) Western blotting for LPCAT3 expression in MOLM-13 cell line transduced with empty vector and LPCAT3-OE. (C–D) The apoptosis analysis of MOLM-13 cell line transduced with empty vector and LPCAT3-OE. Flow cytometry plots of apoptotic ratio in MOLM-13 cell line (C). Statistical analysis of apoptotic ratio in MOLM-13 cell line (D). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (E–F) The cell-cycle analysis of MOLM-13 cell line transduced with empty vector and LPCAT3-OE. Flow cytometric analysis of cell cycle in MOLM-13 cell line (E). Quantification of G0, G1, S/G2/M phases in MOLM-13 cell line (F). Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. (G) Proliferation curves of empty vector and LPCAT3-OE groups in MOLM-13 cell line were measured by CCK-8. Data are presented as mean ± SD (n = 3). Statistical significance was determined using 2-way ANOVA. *p < 0.050, **p < 0.010, ***p < .001. AML = acute myeloid leukemia, ANOVA = analysis of variance, LPCAT3 = lysophosphatidylcholine acyltransferase 3, RT-qPCR = quantitative real-time polymerase chain reaction, SD = standard deviation. To directly assess the role of LPCAT3 in regulating leukemic cell phenotypes, we performed rescue experiments in CRISPR/Cas9-mediated LPCAT3-knockout MOLM-13 cells (sgLPCAT3-2 and sgLPCAT3-3). Wild-type LPCAT3 tagged with 3×flag was re-expressed in LPCAT3-deficient cells, with empty vector serving as a control. Reconstitution of LPCAT3 partially restored cell proliferation, reduced apoptotic cell fractions, and promoted cell-cycle progression compared with vector-transduced cells. These effects were consistently observed in both sgLPCAT3-2 and sgLPCAT3-3 cell lines, supporting a direct functional contribution of LPCAT3 to leukemic cell growth and survival (Figure S1, https://links.lww.com/BS/A164). 3.5. LPCAT3 depletion reduces leukemic burden in vivo To assess the function of LPCAT3 in AML progression in vivo, we performed xenotransplantation experiments using the human AML cell line MOLM-13. MOLM-13 cells stably transduced with either scramble-control or LPCAT3-targeting shRNA were transplanted into 1.2 Gy irradiated NCG mice, a highly immunodeficient strain lacking T, B, and NK cells, to establish an in vivo AML model. At defined time points post-transplantation, peripheral blood, spleen, and bone marrow samples were harvested and analyzed by flow cytometry to quantify human CD45+ leukemic cells (Fig. 5A). The data revealed a reduction in the percentage of human CD45+ cells in peripheral blood of the LPCAT3-depleted group compared with controls (Fig. 5B, C). Furthermore, a dramatic decrease was observed in the bone marrow of the LPCAT3-depleted group compared with the controls (Fig. 5D, E). LPCAT3 deletion delays leukemia progression in vivo. (A) Schematic of the experimental design. (B–C) Flow cytometry plots and quantification of human CD45+ leukemic cells in PB of xenografted mice. Data are presented as mean ± SD (n = 4). Statistical significance was determined using an unpaired Student t test. (D–E) Flow cytometry plots and quantification of human CD45+ leukemic cells in BM of xenografted mice. Data are presented as mean ± SD (n = 4). Statistical significance was determined using an unpaired Student t test. (F–G) Flow cytometry plots and quantification of human CD45+ leukemic cells in SP of xenografted mice. Data are presented as mean ± SD (n = 4). Statistical significance was determined using an unpaired Student t test. *p < 0.050. BM = bone marrow, LPCAT3 = lysophosphatidylcholine acyltransferase 3, PB = peripheral blood, SD = standard deviation, SP = spleen. To determine whether this effect extended to extramedullary sites, spleens from transplanted mice were analyzed, which revealed markedly lower human CD45+ leukemic infiltration in the spleens of LPCAT3-depleted mice (Fig. 5F, G). Complementary histopathological examination of liver, spleen, and kidney tissues further confirmed reduced leukemic infiltration in these organs in the LPCAT3-depleted group compared with controls (Figure S2A, https://links.lww.com/BS/A165). LPCAT3-depleted was associated with a trend toward prolonged survival of AML-bearing mice; however, this difference did not reach statistical significance, likely due to the limited sample size (Figure S2B, https://links.lww.com/BS/A165). These findings indicate that LPCAT3 suppression substantially impairs leukemic engraftment and expansion in the bone marrow microenvironment. 3.6. Transcriptomic profiling implicates that granulocyte chemotaxis pathways are LPCAT3-regulated To elucidate the molecular mechanisms underlying the phenotypic effects of LPCAT3 depletion in AML cells, we performed transcriptomic profiling with MOLM-13 cells transduced with control sgRNA or LPCAT3-targeting sgRNA-3 using RNA-seq. Differential gene expression analysis identified 108 significantly upregulated and 55 downregulated genes upon LPCAT3 knockout, which were visualized in a volcano plot to highlight both the magnitude and statistical significance of these changes (Fig. 6A, Table S2, https://links.lww.com/BS/A168). Gene Ontology (GO) enrichment analysis revealed that the differentially expressed genes were predominantly involved in immune-related processes, including granulocyte activation and chemotaxis, as well as signaling pathways associated with chemotactic responses (Fig. 6B, Table S3, https://links.lww.com/BS/A168). Transcriptomic profiling reveals enrichment of granulocyte chemotaxis–related pathways upon LPCAT3 depletion. (A) Volcano plot of differentially expressed genes from RNA-seq comparing sg-LPCAT3 and sg-control MOLM-13 cells. |log2FC| ≥ 1, p-adjust 0.050. (B) GO enrichment analysis of differentially expressed genes (Top20). (C–E) Chord plot showing the relevant GO terms (C), KEGG terms (D), Reactome terms (E) of enriched biological processes. (F) RT-qPCR analysis for transcriptional levels of upregulated granulocyte chemotaxis-related genes (C3AR1, CCL24, SLAMF1, CCL3L1, PDE4B) and downregulated gene MDK, consistent with RNA-seq findings. Data are presented as mean ± SD (n = 3). Statistical significance was determined using an unpaired Student t test. *p < 0.050, **p < 0.010, ***p < .001. (G) Kaplan–Meier survival analysis of TCGA-LAML patients stratified into high and low CCL24 expression groups using GEPIA2. GO = Gene Ontology, KEGG = Kyoto Encyclopedia of Genes and Genomes, LAML = acute myeloid leukemia, LPCAT3 = lysophosphatidylcholine acyltransferase 3, RT-qPCR = quantitative real-time polymerase chain reaction, SD = standard deviation, TCGA = The Cancer Genome Atlas. To further delineate the interconnections among these pathways, we performed integrated pathway analyses using KEGG, GO, and Reactome databases. The results revealed that LPCAT3 depletion impacts a network of signaling pathways, with considerable overlap among immune response, chemotaxis, and inflammation-related processes (Fig. 6C–E). To validate these transcriptomic findings, we selected a subset of key genes that were differentially expressed and functionally relevant to granulocyte chemotaxis. Specifically, we focused on genes upregulated upon LPCAT3 depletion, including C3AR1, CCL24, SLAMF1, CCL3L1, and PDE4B, as well as the downregulated gene MDK, which has been implicated in cell growth and survival.34–37 qPCR analysis confirmed that the chemotaxis-related genes were indeed significantly upregulated, while MDK expression was reduced, consistent with the RNA-seq results (Fig. 6F). We further examined the association of these genes with patient survival in AML cohorts. Notably, low expression of CCL24 was correlated with shorter overall survival, providing additional clinical validation of our RNA-seq findings (Fig. 6G, Figure S3A–D, https://links.lww.com/BS/A166). Given that RNA-seq analysis revealed enrichment of immune-related gene programs following LPCAT3 knockout, including chemokine-associated pathways, we next sought to determine whether CCL24 contributes functionally to the LPCAT3-regulated phenotypes. CCL24 (eotaxin-2) is a CC chemokine involved in immune cell chemotaxis and has been identified as part of chemokine networks released by AML cells,38,39 although its specific functional role in AML pathogenesis remains poorly defined and is unlikely to act as a dominant driver on its own. These observations suggest that CCL24 may contribute to leukemic cell behavior in a context-dependent manner, supporting its investigation as a downstream effector rather than a primary mediator. To this end, CCL24 expression was silenced in LPCAT3-knockout MOLM-13 cells using 3 independent siRNAs, with a non-targeting siRNA serving as a control. Given the lack of a reliable antibody for CCL24 suitable for immunoblotting, the efficiency of CCL24 knockdown was instead evaluated using an enzyme-linked immunosorbent assay (ELISA) kit to quantify secreted CCL24 levels. Transfection of CCL24-specific siRNAs resulted in a marked reduction in CCL24 protein levels compared with non-targeting controls, confirming effective gene silencing (Figure S4A, https://links.lww.com/BS/A167). Functionally, CCL24 depletion led to a significant acceleration of leukemic cell proliferation (Figure S4B, https://links.lww.com/BS/A167), while the proportion of apoptotic cells was reduced relative to control cells (Figure S4C–D, https://links.lww.com/BS/A167). Cell-cycle analysis revealed a slight shift toward increased S/G2/M phase occupancy after CCL24 knockdown, suggesting a tendency toward accelerated cell-cycle progression, albeit without pronounced statistical significance (Figure S4C–E, https://links.lww.com/BS/A167). These results suggest that CCL24 acts as one of the downstream effectors of LPCAT3-regulated phenotypes. Collectively, these data indicate that LPCAT3 loss reshapes the transcriptional landscape of AML cells, prominently enhancing signaling pathways related to granulocyte chemotaxis. 4. DISCUSSION In this study, our integrated analyses identify LPCAT3 as a novel regulator of AML biology with translational implications. Clinically, LPCAT3 is highly expressed in AML primary samples and correlates with adverse patient outcome, suggesting prognostic utility. Functionally, genetic suppression of LPCAT3 robustly undermines leukemic proliferation, induces apoptosis, enforces G0/G1 arrest, and diminishes in vivo leukemia propagation, providing strong genetic evidence that LPCAT3 supports leukemic cell fitness. LPCAT3, a key enzyme in phospholipid remodeling, is essential for sustaining lipid homeostasis and membrane integrity.10,40 Rapid proliferation of leukemia cells requires dynamic remodeling of membrane lipids to support cell growth and survival.41 As a key regulator of phosphatidylcholine biosynthesis, LPCAT3 modulates the incorporation of PUFAs into phospholipids,42 thereby influencing membrane composition and cellular metabolism.42–44 Dysregulation of LPCAT3 can disrupt lipid balance, leading to altered cell proliferation and survival.45 Transcriptomic analyses in LPCAT3 depletion in AML cells provide mechanistic insights into how LPCAT3 modulates AML cell biology. The reduced proliferation and increased apoptosis observed in LPCAT3-depleted AML cells can be mechanistically explained by our RNA-seq results, which revealed widespread transcriptional reprogramming. Specifically, LPCAT3 depletion led to downregulation of cell cycle and proliferation-related genes such as PIMREG,46 TBX3,47 WNT7B,48 and TRIB2,49,50 as well as growth- and survival-associated genes like MDK.51 These transcriptional alterations are consistent with and provide a molecular basis for the phenotypic changes we observed. These findings suggest that LPCAT3 supports AML cell proliferation and survival not only by regulating intrinsic metabolic and growth-promoting pathways but also by regulating chemotactic signaling that may mediate immune interactions. LPCAT3 plays a central role in phospholipid remodeling and integrates multiple metabolic pathways that are closely linked to leukemic cell biology. As the key acyltransferase in the Lands cycle, LPCAT3 regulates the incorporation of PUFAs into membrane phospholipids, thereby shaping membrane composition, fluidity, and lipid raft integrity.52,53 These structural features critically influence the spatial organization and signaling activity of surface receptors, including chemokine receptors, suggesting that LPCAT3-mediated lipid remodeling may directly modulate the strength and dynamics of chemotactic signaling.54,55 In addition, LPCAT3 determines the abundance of PUFA-containing phospholipids that serve as substrates for lipid peroxidation, positioning it as an important regulator of ferroptosis susceptibility—a metabolic–cell death axis increasingly recognized as influencing AML stress adaptation and therapeutic response.56–58 Furthermore, LPCAT3 intersects with inflammatory lipid signaling pathways, including eicosanoid synthesis and nuclear factor kappa B (NF-κB)–dependent transcription, both of which depend on PUFA availability and are known to regulate cytokine and chemokine networks relevant to leukemic cell migration and bone-marrow niche interactions.12,20,59 Given the dependence of AML trafficking on CXCR4–CXCL12 signaling, a process tightly regulated by membrane lipid microdomains, LPCAT3 activity may further influence leukemic cell homing and retention by altering receptor clustering or downstream pathways such as phosphoinositide 3-kinase (PI3K)–protein kinase B (AKT) and mitogen-activated protein kinase (MAPK).60 Consistent with this mechanistic framework, The observed upregulation of chemotaxis-related genes, including C3AR1, CCL24, SLAMF1, and CCL3L1, following LPCAT3 loss reveals a previously unrecognized role for LPCAT3 in modulating the AML immune microenvironment.61–63 Clinically, the correlation between low CCL24 expression and poorer patient survival implies that LPCAT3-mediated regulation of chemotactic signaling may contribute to disease aggressiveness.64 Modulating chemotactic signaling via LPCAT3 inhibition could enhance immune-mediated surveillance and potentially improve outcomes.65 Together, these data indicate that LPCAT3 acts as a coordinator of multiple cellular programming, balancing intrinsic proliferative capacity with extrinsic signaling that influences immune interactions.66 Such dual regulation highlights the LPCAT3 as a multifaceted contributor to AML pathobiology and underscores its potential as a therapeutic target for strategies aimed at both leukemia cell-intrinsic vulnerabilities and modulation of the immune microenvironment. Several limitations of this study should be acknowledged. The number of primary AML samples available for validation was limited, and most functional analyses were performed using cell line-based and xenograft models; validation in larger patient cohorts and patient-derived xenograft (PDX) models will further strengthen the clinical relevance of our findings. In addition, although transcriptomic analyses revealed enrichment of immune- and chemotaxis-related programs and identified lipid metabolism–associated pathways upon LPCAT3 depletion, RNA-seq does not directly assess LPCAT3 enzymatic activity or global lipidomic alterations. Therefore, the precise mechanisms by which LPCAT3 regulates leukemic progression through lipid remodeling remain to be fully elucidated. Future studies incorporating functional lipidomic profiling and signaling analyses will be required to clarify how LPCAT3 orchestrates lipid-dependent regulation of leukemic cell behavior. Finally, it should be noted that the precise molecular mechanism by which LPCAT3 regulates CCL24 expression was not directly investigated in this study and therefore requires further mechanistic exploration. 5. CONCLUSION This study provides the first comprehensive characterization of LPCAT3 in AML, establishing its role in supporting leukemic proliferation and survival, and regulating granulocyte chemotaxis–related pathways. LPCAT3 overexpression correlates with poor prognosis, and LPCAT3 suppression reduces leukemia burden and prolongs survival. By linking membrane phospholipid remodeling to granulocyte chemotaxis–related transcriptional programs, our findings nominate LPCAT3 as both a prognostic biomarker and a therapeutic vulnerability warranting further translational investigation. ACKNOWLEDGMENTS This work was supported by funds from the National Key R&D Program of China (2022YFA1103300 to W.Y. and Y.C., 2024YFC2510500 to W.Y.); the National Natural Science Foundation of China (82170117 to Y.C., 82170135 to W.Y.); the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, CIFMS (2023-I2M-2-007 and 2021-I2M-1-040 to W.Y.). ETHICAL APPROVAL The studies concerning human subjects were reviewed and approved by the ethics committee of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (NSFC2021017-EC-2). All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. All procedures were performed in accordance with the institutional guidelines for the care and use of laboratory animals. AUTHOR CONTRIBUTIONS Y.C. and W.Y. supervised the research and revised the paper. M.C., L.C., Y.C., and W.Y. conceived the project. M.C. and L.C. performed most of the experiments, analyzed the data, wrote and revised the paper. Y.H., M.H., Y.L., W.L., and M.Z. assisted with experiments and data analysis. All authors read and approved the final manuscript. Supplementary Material